Dupilumab safe, effective for atopic dermatitis
Dupilumab, at dose regimens of 300 mg once weekly (qw) or once every 2 weeks (q2w), is effective and safe for atopic dermatitis, a recent meta-analysis has shown.
Pooled analysis of six trials (n=2,447) revealed that there was a significant decrease in the Eczema Area and Severity Index (EASI) scores following dupilumab treatment (standardized mean difference [SMD], –0.89; 94 percent CI, –1.00 to –0.78; p<0.00001).
The effect remained significant in both the 300 mg qw (SMD, –0.93; –1.10 to –0.76; p<0.00001) and q2w (SMD, –0.86; –1.02 to –0.71; p<0.00001) dosing regimens.
Dupilumab was better than placebo even when using other efficacy measures: percentage of body surface area (SMD, –0.83; –0.90 to –0.75; p<0.00001), Investigators Global Assessment response (risk ratio [RR], 3.82; 3.23–4.51; p<0.00001), pruritus numeric rating scale score (SMD, –0.81; –0.96 to –0.66; p<0.00001) and Dermatology Life Quality Index (SMD, –0.78; –0.89 to –0.66; p<0.00001).
In all cases above, both dosing regimens were significantly effective.
While all trials reported adverse events, the overall rates were statistically similar between dupilumab and placebo (42 percent vs 43 percent; RR, 1.0; 0.96–1.04; p=0.83). The rates of patients with ≥1 adverse event for the 300-mg qw and q2w dosing regimens were 32.8 percent (RR, 0.99; 0.94–1.05; p=0.81) and 41.9 percent (RR, 1.0; 0.94–1.06; p=0.97), respectively.
Accessing the databases of CBM, the Cochrane Library, Embase and PubMed, researchers identified randomized controlled trials of dupilumab treatment on adult atopic dermatitis patients. Observational, case-control and nonblinded studies were excluded from the meta-analysis.